Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer

NCT06900595 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06900595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06900595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
February 22, 2026
Completion date
June 2, 2029
Enrollment
48 (estimated)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced adrenal cortical carcinoma, metastatic adrenal cortical carcinoma, recurrent adrenal cortical carcinoma, stage iii adrenal cortical carcinoma ajcc v8, stage iv adrenal cortical carcinoma ajcc v8, unresectable adrenal cortical carcinoma